<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03600883</url>
  </required_header>
  <id_info>
    <org_study_id>20170543</org_study_id>
    <nct_id>NCT03600883</nct_id>
  </id_info>
  <brief_title>A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of AMG 510 in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)</brief_title>
  <official_title>A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreaK 100)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the safety and tolerability of AMG 510 in adult subjects with KRAS p.G12C mutant&#xD;
      advanced solid tumors.&#xD;
&#xD;
      Estimate the maximum tolerated dose (MTD) and/or a recommended phase 2 dose (RP2D) in adult&#xD;
      subjects with KRAS p.G12C mutant advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 27, 2018</start_date>
  <completion_date type="Anticipated">November 11, 2024</completion_date>
  <primary_completion_date type="Anticipated">November 11, 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary: Number of subjects with treatment-emergent adverse events</measure>
    <time_frame>24 Months</time_frame>
    <description>Treatment-emergent adverse events will be a primary outcome measure for the following groups:&#xD;
Phase 1 Dose Exploration Part 1 monotherapy&#xD;
Phase 1 Dose Expansion Part 2 monotherapy&#xD;
Phase 1 combination arm with AMG 510 and anti PD-1/L1&#xD;
Phase 1 monotherapy treatment naïve advanced NSCLC&#xD;
Phase 2 monotherapy dose comparison</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary: Number of subjects with treatment-related adverse events</measure>
    <time_frame>24 Months</time_frame>
    <description>Treatment-related adverse events will be a primary outcome measure for the following groups:&#xD;
Phase 1 Dose Exploration Part 1 monotherapy&#xD;
Phase 1 Dose Expansion Part 2 monotherapy&#xD;
Phase 1 combination arm with AMG 510 and anti PD-1/L1&#xD;
Phase 1 monotherapy treatment naïve advanced NSCLC</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary: Number of subjects with grade ≥3 treatment-emergent adverse events</measure>
    <time_frame>24 Months</time_frame>
    <description>Grade ≥3 treatment-emergent adverse events will be a primary outcome measure in the following group:&#xD;
- Phase 2 monotherapy dose comparison</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary: Number of subjects with serious adverse events</measure>
    <time_frame>24 Months</time_frame>
    <description>Serious adverse events will be a primary outcome measure in the following group:&#xD;
- Phase 2 monotherapy dose comparison</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary: Number of subjects with adverse events of interest</measure>
    <time_frame>24 Months</time_frame>
    <description>Adverse events of interest will be a primary outcome measure in the following group:&#xD;
- Phase 2 monotherapy dose comparison</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary: Number of subjects with clinically significant changes in vital signs</measure>
    <time_frame>Baseline to 24 Months</time_frame>
    <description>Vital signs will be a primary outcome measure for the following groups:&#xD;
Phase 1 Dose Exploration Part 1 monotherapy&#xD;
Phase 1 Dose Expansion Part 2 monotherapy&#xD;
Phase 1 combination arm with AMG 510 and anti PD-1/L1&#xD;
Phase 1 monotherapy treatment naïve advanced NSCLC</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary: Number of subjects with clinically significant changes in physical examination results</measure>
    <time_frame>Baseline to 24 Months</time_frame>
    <description>Physical examinations will be a primary outcome measure for the following groups:&#xD;
Phase 1 Dose Exploration Part 1 monotherapy&#xD;
Phase 1 Dose Expansion Part 2 monotherapy&#xD;
Phase 1 combination arm with AMG 510 and anti PD-1/L1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary: Number of subjects with clinically significant changes on electrocardiograms (ECGs)</measure>
    <time_frame>Baseline to 24 Months</time_frame>
    <description>ECGs will be a primary outcome measure for the following groups:&#xD;
Phase 1 Dose Exploration Part 1 monotherapy&#xD;
Phase 1 Dose Expansion Part 2 monotherapy&#xD;
Phase 1 combination arm with AMG 510 and anti PD-1/L1&#xD;
Phase 1 monotherapy treatment naïve advanced NSCLC</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary: Number of subjects with clinically significant changes in clinical laboratory values</measure>
    <time_frame>Baseline to 24 Months</time_frame>
    <description>Abnormal clinical laboratory values will be a primary outcome measure for the following groups:&#xD;
Phase 1 Dose Exploration Part 1 monotherapy&#xD;
Phase 1 Dose Expansion Part 2 monotherapy&#xD;
Phase 1 combination arm with AMG 510 and anti PD-1/L1&#xD;
Phase 1 monotherapy treatment naïve advanced NSCLC</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary: Number of subjects with dose-limiting toxicities (DLTs)</measure>
    <time_frame>21 Days</time_frame>
    <description>DLTs will be a primary outcome measure for the following groups:&#xD;
Phase 1 Dose Exploration Part 1 monotherapy&#xD;
Phase 1 Dose Expansion Part 2 monotherapy&#xD;
Phase 1 combination arm with AMG 510 and anti PD-1/L1&#xD;
Phase 1 monotherapy treatment naïve advanced NSCLC</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary: Objective response rate (ORR) as assessed by RECIST 1.1 criteria</measure>
    <time_frame>24 Months</time_frame>
    <description>ORR will be a primary outcome measure in the following group:&#xD;
Phase 1 monotherapy treatment naïve advanced NSCLC&#xD;
Phase 2 monotherapy&#xD;
Phase 2 monotherapy dose comparison</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary: Duration of response (DOR) as assessed by RECIST 1.1 criteria</measure>
    <time_frame>24 Months</time_frame>
    <description>DOR will be a primary outcome measure in the following group:&#xD;
- Phase 1 monotherapy treatment naïve advanced NSCLC</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary: Disease control as assessed by RECIST 1.1 criteria</measure>
    <time_frame>24 Months</time_frame>
    <description>Disease control will be a primary outcome measure in the following group:&#xD;
- Phase 1 monotherapy treatment naïve advanced NSCLC</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary: Duration of stable disease (SD) as assessed by RECIST 1.1 criteria</measure>
    <time_frame>24 Months</time_frame>
    <description>Duration of SD will be a primary outcome measure in the following group:&#xD;
- Phase 1 monotherapy treatment naïve advanced NSCLC</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary: Time to response (TTR) as assessed by RECIST 1.1 criteria</measure>
    <time_frame>24 Months</time_frame>
    <description>TTR will be a primary outcome measure in the following group:&#xD;
- Phase 1 monotherapy treatment naïve advanced NSCLC</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary: Plasma concentration (Cmax) of AMG 510</measure>
    <time_frame>15 Weeks</time_frame>
    <description>Cmax will be a secondary outcome measure for the following groups:&#xD;
Phase 1 Dose Exploration Part 1 monotherapy&#xD;
Phase 1 Dose Expansion Part 2 monotherapy&#xD;
Phase 2 monotherapy&#xD;
Phase 1 combination arm with AMG 510 and anti PD-1/L1&#xD;
Phase 1 monotherapy treatment naïve advanced NSCLC&#xD;
Phase 2 monotherapy dose comparison</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary: Plasma concentration (Cmax) of midazolam</measure>
    <time_frame>16 Days</time_frame>
    <description>Cmax of midazolam will be a secondary outcome measure for the subgroup of subjects who were administered midazolam in the following group:&#xD;
- Phase 1 monotherapy treatment naïve advanced NSCLC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary: Time to achieve Cmax (Tmax) of AMG 510</measure>
    <time_frame>15 Weeks</time_frame>
    <description>Tmax will be a secondary outcome measure for the following groups:&#xD;
Phase 1 Dose Exploration Part 1 monotherapy&#xD;
Phase 1 Dose Expansion Part 2 monotherapy&#xD;
Phase 2 monotherapy&#xD;
Phase 1 combination arm with AMG 510 and anti PD-1/L1&#xD;
Phase 1 monotherapy treatment naïve advanced NSCLC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary: Area under the plasma concentration-time curve (AUC) of AMG 510</measure>
    <time_frame>15 Weeks</time_frame>
    <description>AUC will be a secondary outcome measure for the following groups:&#xD;
Phase 1 Dose Exploration Part 1 monotherapy&#xD;
Phase 1 Dose Expansion Part 2 monotherapy&#xD;
Phase 2 monotherapy&#xD;
Phase 1 combination arm with AMG 510 and anti PD-1/L1&#xD;
Phase 1 monotherapy treatment naïve advanced NSCLC&#xD;
Phase 2 monotherapy dose comparison</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary: Area under the plasma concentration-time curve (AUC) of midazolam</measure>
    <time_frame>16 Days</time_frame>
    <description>AUC of midazolam will be a secondary outcome measure for the subgroup of subjects who were administered midazolam in the following group:&#xD;
- Phase 1 monotherapy treatment naïve advanced NSCLC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary: Clearance of midazolam from the plasma</measure>
    <time_frame>16 Days</time_frame>
    <description>Clearance of midazolam from the plasma will be a secondary outcome measure for the subgroup of subjects who were administered midazolam in the following group:&#xD;
- Phase 1 monotherapy treatment naïve advanced NSCLC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary: Terminal half-life (t1/2) of midazolam</measure>
    <time_frame>16 Days</time_frame>
    <description>t1/2 of midazolam will be a secondary outcome measure for the subgroup of subjects who were administered midazolam in the following group:&#xD;
- Phase 1 monotherapy treatment naïve advanced NSCLC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary: Objective response rate (ORR) as assessed by RECIST 1.1 criteria</measure>
    <time_frame>24 Months</time_frame>
    <description>ORR will be a secondary outcome measure for the following groups:&#xD;
Phase 1 Dose Exploration Part 1 monotherapy&#xD;
Phase 1 Dose Expansion Part 2 monotherapy&#xD;
Phase 1 combination arm with AMG 510 and anti PD-1/L1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary: Duration of response (DOR) as assessed by RECIST 1.1 criteria</measure>
    <time_frame>24 Months</time_frame>
    <description>DOR will be a secondary outcome measure for the following groups:&#xD;
Phase 1 Dose Exploration Part 1 monotherapy&#xD;
Phase 1 Dose Expansion Part 2 monotherapy&#xD;
Phase 2 monotherapy&#xD;
Phase 1 combination arm with AMG 510 and anti PD-1/L1&#xD;
Phase 2 monotherapy dose comparison</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary: Disease control as assessed by RECIST 1.1 criteria</measure>
    <time_frame>24 Months</time_frame>
    <description>DOR will be a secondary outcome measure for the following groups:&#xD;
Phase 1 Dose Exploration Part 1 monotherapy&#xD;
Phase 1 Dose Expansion Part 2 monotherapy&#xD;
Phase 2 monotherapy&#xD;
Phase 1 combination arm with AMG 510 and anti PD-1/L1&#xD;
Phase 2 monotherapy dose comparison</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary: Progression-free survival (PFS) as assessed by RECIST 1.1 criteria</measure>
    <time_frame>24 Months</time_frame>
    <description>PFS will be a secondary outcome measure for the following groups:&#xD;
Phase 1 Dose Exploration Part 1 monotherapy&#xD;
Phase 1 Dose Expansion Part 2 monotherapy&#xD;
Phase 2 monotherapy&#xD;
Phase 1 combination arm with AMG 510 and anti PD-1/L1&#xD;
Phase 2 monotherapy dose comparison&#xD;
Phase 1 monotherapy treatment naïve advanced NSCLC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary: Duration of stable disease (SD) as assessed by RECIST 1.1 criteria</measure>
    <time_frame>24 Months</time_frame>
    <description>Duration of SD will be a secondary outcome measure for the following groups:&#xD;
Phase 1 Dose Exploration Part 1 monotherapy&#xD;
Phase 1 Dose Expansion Part 2 monotherapy&#xD;
Phase 1 combination arm with AMG 510 and anti PD-1/L1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary: Depth of response (best percentage change from baseline in lesion sum diameters) as assessed by RECIST 1.1 criteria</measure>
    <time_frame>Baseline to 24 Months</time_frame>
    <description>Depth of response will be a secondary outcome measure for the following group:&#xD;
- Phase 2 monotherapy dose comparison</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary: Time to response (TTR) as assessed by RECIST 1.1 criteria</measure>
    <time_frame>24 Months</time_frame>
    <description>DOR will be a secondary outcome measure for the following groups:&#xD;
Phase 1 Dose Exploration Part 1 monotherapy&#xD;
Phase 1 Dose Expansion Part 2 monotherapy&#xD;
Phase 2 monotherapy&#xD;
Phase 1 combination arm with AMG 510 and anti PD-1/L1&#xD;
Phase 2 monotherapy dose comparison</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary: Overall survival (OS)</measure>
    <time_frame>24 Months</time_frame>
    <description>OS will be a secondary outcome measure for the following groups:&#xD;
Phase 1 Dose Exploration Part 1 monotherapy&#xD;
Phase 1 Dose Expansion Part 2 monotherapy&#xD;
Phase 2 monotherapy&#xD;
Phase 1 combination arm with AMG 510 and anti PD-1/L1&#xD;
Phase 2 monotherapy dose comparison&#xD;
Phase 1 monotherapy treatment naïve advanced NSCLC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary: AMG 510 exposure and QTc interval relationship</measure>
    <time_frame>24 Months</time_frame>
    <description>AMG 510 exposure and QTc interval relationship will be a secondary outcome measure for the following groups:&#xD;
Phase 1 Dose Exploration Part 1 monotherapy&#xD;
Phase 1 Dose Expansion Part 2 monotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary: Progression-free survival (PFS) at 6 months</measure>
    <time_frame>6 Months</time_frame>
    <description>PFS at 6 months will be a secondary outcome measure for the following group:&#xD;
- Phase 2 monotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary: Progression-free survival (PFS) at 12 months</measure>
    <time_frame>12 Months</time_frame>
    <description>PFS at 12 months will be a secondary outcome measure for the following group:&#xD;
- Phase 2 monotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary: Overall survival (OS) at 12 months</measure>
    <time_frame>12 Months</time_frame>
    <description>OS at 12 months will be a secondary outcome measure for the following group:&#xD;
- Phase 2 monotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary: Number of subjects with treatment-emergent adverse events</measure>
    <time_frame>24 Months</time_frame>
    <description>Treatment-emergent adverse events will be a secondary outcome measure for the following group:&#xD;
- Phase 2 monotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary: Number of subjects with grade ≥3 treatment-emergent adverse events</measure>
    <time_frame>24 Months</time_frame>
    <description>Grade ≥3 treatment-emergent adverse events will be a secondary outcome measure for the following group:&#xD;
- Phase 2 monotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary: Impact of treatment on disease-related symptoms and health related quality of life (HRQOL) as assessed by EORTC QLQ-C30</measure>
    <time_frame>24 Months</time_frame>
    <description>Impact of treatment on disease-related symptoms and HRQOL will be a secondary outcome measure for the following group:&#xD;
- Phase 2 monotherapy dose comparison</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary: Impact of treatment on disease-related symptoms and HRQOL as assessed by disease-specific modules Quality-of-Life Questionnaire Lung Cancer Module (QLQ LC13)</measure>
    <time_frame>24 Months</time_frame>
    <description>Impact of treatment on disease-related symptoms and HRQOL will be a secondary outcome measure for the following group:&#xD;
- Phase 2 monotherapy dose comparison</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary: Impact of treatment on disease-related symptoms and HRQOL as assessed by non-small cell lung cancer symptom assessment questionnaire (NSCLC SAQ) for NSCLC</measure>
    <time_frame>24 Months</time_frame>
    <description>Impact of treatment on disease-related symptoms and HRQOL will be a secondary outcome measure for the following group:&#xD;
- Phase 2 monotherapy dose comparison</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary: Impact of treatment on disease-related symptoms and HRQOL as assessed by Patient Global Impression of Severity (PGIS)</measure>
    <time_frame>24 Months</time_frame>
    <description>Impact of treatment on disease-related symptoms and HRQOL will be a secondary outcome measure for the following group:&#xD;
- Phase 2 monotherapy dose comparison</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary: Impact of treatment on disease-related symptoms and HRQOL as assessed by Patient Global Impression of Change (PGIC) in cough, dyspnea and chest pain for NSCLC</measure>
    <time_frame>24 Months</time_frame>
    <description>Impact of treatment on disease-related symptoms and HRQOL will be a secondary outcome measure for the following group:&#xD;
- Phase 2 monotherapy dose comparison</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary: Treatment-related symptoms and impact on the subject as assessed by EORTC QLQ-C30</measure>
    <time_frame>24 Months</time_frame>
    <description>Treament related symptoms and impact on the subject will be a secondary outcome measure for the following group:&#xD;
- Phase 2 monotherapy dose comparison</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary: Treatment-related symptoms and impact on the subject as assessed by selected questions from the Patient-reported Outcome of the Common Terminology Criteria for Adverse Events (PRO-CTCAE library)</measure>
    <time_frame>24 Months</time_frame>
    <description>Treatment-related symptoms and impact on the subject will be a secondary outcome measure for the following group:&#xD;
- Phase 2 monotherapy dose comparison</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary: Treatment-related symptoms and impact on the subject as assessed by a single item about symptom bother, item GP5 of the Functional Assessment of Cancer Therapy - General (FACT-G)</measure>
    <time_frame>24 Months</time_frame>
    <description>Treatment-related symptoms and impact on the subject will be a secondary outcome measure for the following group:&#xD;
- Phase 2 monotherapy dose comparison</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary: Change from baseline in physical function as assessed by EORTC QLQ-C30</measure>
    <time_frame>Baseline to 24 Months</time_frame>
    <description>Treatment-related symptoms and impact on the subject will be a secondary outcome measure for the following group:&#xD;
- Phase 2 monotherapy dose comparison</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">733</enrollment>
  <condition>KRAS p.G12C Mutant Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Phase 1 Dose Exploration Part 1 monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohorts with food effect and alternative dosing regimens&#xD;
Enrollment into the dose exploration cohorts may be from any eligible solid tumor type. Dose escalation will begin with 2-4 subjects treated at the lowest planned dose level of 180 mg. If no DLT is observed, dose escalation will continue to the next planned dose cohort</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1 Dose Expansion Part 2 monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Upon completing the dose exploration part of the study, dose expansion may proceed with 3 groups consisting of subjects with KRAS p.G12C mutant advanced solid tumors. Dose expansion in these 3 groups may be done concurrently</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Additional subjects will be enrolled in the dose expansion to confirm the recommended phase 2 dose. Enrollment into phase 2 will be opened after confirmation of the recommended phase 2 dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1 combination arm with AMG 510 and anti PD-1/L1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Additional subjects will be enrolled into the combination arm with AMG 510 in combination with an anti (PD-1/L1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1 monotherapy treatment naive advanced NSCLC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Separate cohort of part 1 dose expansion subjects to evaluate the safety and clinical activity of AMG 510 administered orally once daily in subjects with previously untreated advanced non-small cell lung cancer (NSCLC). Drug-drug interaction will be evaluated in 6 of the subjects enrolled in the treatment naive cohort by adding Midazolam alone on Day -1 and in combination with AMG 510 on Day 15 of Cycle 1, where each cycle is 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 monotherapy dose comparison</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with NSCLC will be enrolled in a dose comparison study evaluating safety and efficacy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 510</intervention_name>
    <description>Characterize the pharmacokinetics (PK) of AMG 510 following administration as an oral Tablet formulation</description>
    <arm_group_label>Phase 1 Dose Expansion Part 2 monotherapy</arm_group_label>
    <arm_group_label>Phase 1 Dose Exploration Part 1 monotherapy</arm_group_label>
    <arm_group_label>Phase 1 combination arm with AMG 510 and anti PD-1/L1</arm_group_label>
    <arm_group_label>Phase 1 monotherapy treatment naive advanced NSCLC</arm_group_label>
    <arm_group_label>Phase 2 monotherapy</arm_group_label>
    <arm_group_label>Phase 2 monotherapy dose comparison</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti PD-1/L1</intervention_name>
    <description>Administered as an intravenous (IV) infusion</description>
    <arm_group_label>Phase 1 combination arm with AMG 510 and anti PD-1/L1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>Administered as an oral hydrochloride (HCI) syrup</description>
    <arm_group_label>Phase 1 monotherapy treatment naive advanced NSCLC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men or women greater than or equal to 18 years old.&#xD;
&#xD;
          -  Pathologically documented, locally-advanced or metastatic malignancy with, KRAS p.G12C&#xD;
             mutation identified through molecular testing.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Active brain metastases from non-brain tumors.&#xD;
&#xD;
          -  Myocardial infarction within 6 months of study day 1.&#xD;
&#xD;
          -  Gastrointestinal (GI) tract disease causing the inability to take oral medication.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amgen Call Center</last_name>
    <phone>866-572-6436</phone>
    <email>medinfo@amgen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California at SF</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sarcoma Oncology Research Center LLC</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute at HealthONE</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Smilow Cancer Hospital at Yale New Haven</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Oncology Hematology Consultants Helen F Graham Cancer Center</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Florida Health</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AdventHealth Orlando Infusion Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>American Oncology Partners of Maryland, PA</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110-1093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Laura and Isaac Perlmutter Cancer Center at New York University Langone</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center, Morris Cancer Clinic</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center Cancer Pavillion</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gibbs Cancer Center and Research Institute - Spartanburg</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Oncology Austin Central</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Oncology Baylor</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>US Oncology Research Investigational Products Center</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists PC</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Blue Ridge Cancer Care</name>
      <address>
        <city>Salem</city>
        <state>Virginia</state>
        <zip>24153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Scientia Clinical Research Ltd</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Queen Elizabeth Hospital</name>
      <address>
        <city>Woodville South</city>
        <state>South Australia</state>
        <zip>5011</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitaet Graz</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitaet Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Krems</name>
      <address>
        <city>Krems</city>
        <zip>3500</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Allgemeines Krankenhaus Wien</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Nord - Klinik Floridsdorf</name>
      <address>
        <city>Wien</city>
        <zip>1210</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Bruxelles</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Grand Hopital de Charleroi</name>
      <address>
        <city>Charleroi</city>
        <zip>6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Oost-Limburg</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jessa Ziekenhuis - Campus Virga Jesse</name>
      <address>
        <city>Hasselt</city>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Leuven - Campus Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Liege</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AZ Delta Campus Rumbeke</name>
      <address>
        <city>Roeselare</city>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Irmandade da Santa Casa de Misericordia de Porto Alegre, Nucleo de Novos Tratamentos em Cancer</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90050-170</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Sao Lucas da Pontificia Universidade Catolica do Rio Grande do Sul</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90610-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sociedade Beneficente de Senhoras Hospital Sirio Libanes</name>
      <address>
        <city>Sao Paulo</city>
        <state>São Paulo</state>
        <zip>01308-050</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oncologia Rede D´Or</name>
      <address>
        <city>Sao Paulo</city>
        <state>São Paulo</state>
        <zip>04501-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de Base de Sao Jose do Rio Preto</name>
      <address>
        <city>São José do Rio Preto</city>
        <state>São Paulo</state>
        <zip>15090-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto Coi</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>22793-080</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>London Regional Cancer Program, London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital Cancer Centre</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal de Créteil</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital de la Timone</name>
      <address>
        <city>Marseille cedex 5</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Koln</name>
      <address>
        <city>Köln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität München Campus Grosshadern</name>
      <address>
        <city>München</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Henry Dunant Hospital Center</name>
      <address>
        <city>Athens</city>
        <zip>11526</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Metropolitan Hospital</name>
      <address>
        <city>Athens</city>
        <zip>18547</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital of Heraklion</name>
      <address>
        <city>Heraklion - Crete</city>
        <zip>71110</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Theagenion Cancer Hospital</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54007</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Agios Loukas Clinic</name>
      <address>
        <city>Thessaloniki</city>
        <zip>55236</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Somogy Megyei Kaposi Mor Oktato Korhaz</name>
      <address>
        <city>Kaposvar</city>
        <zip>7400</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fejer Megyei Szent Gyorgy Egyetemi Oktato Korhaz</name>
      <address>
        <city>Szekesfehervar</city>
        <zip>8000</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Szent Borbala Korhaz</name>
      <address>
        <city>Tatabanya</city>
        <zip>2800</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tudogyogyintezet Torokbalint</name>
      <address>
        <city>Torokbalint</city>
        <zip>2045</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aichi Cancer Center Hospital</name>
      <address>
        <city>Nagoya-shi</city>
        <state>Aichi</state>
        <zip>464-8681</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East</name>
      <address>
        <city>Kashiwa-shi</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Shikoku Cancer Center</name>
      <address>
        <city>Matsuyama-shi</city>
        <state>Ehime</state>
        <zip>791-0280</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Kyushu Cancer Center</name>
      <address>
        <city>Fukuoka-shi</city>
        <state>Fukuoka</state>
        <zip>811-1395</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Hokkaido Cancer Center</name>
      <address>
        <city>Sapporo-shi</city>
        <state>Hokkaido</state>
        <zip>003-0804</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St Marianna University School of Medicine Hospital</name>
      <address>
        <city>Kawasaki-shi</city>
        <state>Kanagawa</state>
        <zip>216-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kanagawa Prefectural Hospital Organization Kanagawa Cancer Center</name>
      <address>
        <city>Yokohama-shi</city>
        <state>Kanagawa</state>
        <zip>241-8515</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sendai Kousei Hospital</name>
      <address>
        <city>Sendai-shi</city>
        <state>Miyagi</state>
        <zip>980-0873</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Niigata Cancer Center Hospital</name>
      <address>
        <city>Niigata-shi</city>
        <state>Niigata</state>
        <zip>951-8566</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Okayama University Hospital</name>
      <address>
        <city>Okayama-shi</city>
        <state>Okayama</state>
        <zip>700-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kansai Medical University Hospital</name>
      <address>
        <city>Hirakata-shi</city>
        <state>Osaka</state>
        <zip>573-1191</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Osaka International Cancer Institute</name>
      <address>
        <city>Osaka-shi</city>
        <state>Osaka</state>
        <zip>541-8567</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shizuoka Cancer Center</name>
      <address>
        <city>Sunto-gun</city>
        <state>Shizuoka</state>
        <zip>411-8777</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Cancer Institute Hospital of Japanese Foundation for Cancer Research</name>
      <address>
        <city>Koto-ku</city>
        <state>Tokyo</state>
        <zip>135-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wakayama Medical University Hospital</name>
      <address>
        <city>Wakayama-shi</city>
        <state>Wakayama</state>
        <zip>641-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si, Gyeonggi-do</city>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea Seoul St Marys Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Severance Hospital Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Unidade Local de Saude de Matosinhos, EPE - Hospital Pedro Hispano</name>
      <address>
        <city>Matosinhos</city>
        <zip>4464-513</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Cuf porto</name>
      <address>
        <city>Porto</city>
        <zip>4100-180</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institutul Oncologic, Prof Dr Alexandru Trestioreanu</name>
      <address>
        <city>Bucuresti</city>
        <zip>022328</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrul de Radioterapie Amethyst Cluj</name>
      <address>
        <city>Cluj Napoca</city>
        <zip>407280</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>SC Medisprof SRL</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400124</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrul de Oncologie Sf Nectarie SRL</name>
      <address>
        <city>Craiova</city>
        <zip>200347</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>SC Oncomed SRL</name>
      <address>
        <city>Timisoara</city>
        <zip>300239</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañon</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fundacion Jimenez Diaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Madrid Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsspital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopitaux Universitaires de Geneve</name>
      <address>
        <city>Geneve</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsspital Zuerich</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <reference>
    <citation>Canon J, Rex K, Saiki AY, Mohr C, Cooke K, Bagal D, Gaida K, Holt T, Knutson CG, Koppada N, Lanman BA, Werner J, Rapaport AS, San Miguel T, Ortiz R, Osgood T, Sun JR, Zhu X, McCarter JD, Volak LP, Houk BE, Fakih MG, O'Neil BH, Price TJ, Falchook GS, Desai J, Kuo J, Govindan R, Hong DS, Ouyang W, Henary H, Arvedson T, Cee VJ, Lipford JR. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature. 2019 Nov;575(7781):217-223. doi: 10.1038/s41586-019-1694-1. Epub 2019 Oct 30.</citation>
    <PMID>31666701</PMID>
  </reference>
  <reference>
    <citation>Skoulidis F, Li BT, Dy GK, Price TJ, Falchook GS, Wolf J, Italiano A, Schuler M, Borghaei H, Barlesi F, Kato T, Curioni-Fontecedro A, Sacher A, Spira A, Ramalingam SS, Takahashi T, Besse B, Anderson A, Ang A, Tran Q, Mather O, Henary H, Ngarmchamnanrith G, Friberg G, Velcheti V, Govindan R. Sotorasib for Lung Cancers with KRAS p.G12C Mutation. N Engl J Med. 2021 Jun 24;384(25):2371-2381. doi: 10.1056/NEJMoa2103695. Epub 2021 Jun 4.</citation>
    <PMID>34096690</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 26, 2018</study_first_submitted>
  <study_first_submitted_qc>July 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2018</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.</ipd_time_frame>
    <ipd_access_criteria>Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.</ipd_access_criteria>
    <ipd_url>https://www.amgen.com/datasharing</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

